• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性癌症中意义不明的变异个体的临床管理:系统评价和荟萃分析。

Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.

机构信息

Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Clinical Cancer Genetics and the Cancer Prevention and Control Platform, Moon Shots Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Clin Genet. 2021 Aug;100(2):119-131. doi: 10.1111/cge.13966. Epub 2021 Apr 21.

DOI:10.1111/cge.13966
PMID:33843052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8672382/
Abstract

Improper medical use of variant of uncertain significance (VUS) remains a concern in hereditary cancer genetic testing. The goal of this study was to assess the association between pathogenic and likely pathogenic (P/LP), VUS, and benign and likely benign (B/LB) genetic test results and cancer-related surgical and screening management. Systematic searches of Medline, Embase, EBSCO CINAHL Plus, and PsycINFO were conducted from 1946 to August 26, 2020. Eligible studies included individuals with cancer genetic test result and surgical or screening management outcomes. We reviewed 885 abstracts and 22 studies that reported relevant surgical and screening outcomes were included. Meta-analysis revealed significantly higher surgical rates among individuals with P/LP than among those with VUS for therapeutic mastectomy with contralateral prophylactic mastectomy (OR = 7.35, 95% CI, 4.14-13.64), prophylactic mastectomy (OR = 3.05, 95% CI, 1.5-6.19), and oophorectomy (OR = 6.46, 95% CI, 3.64-11.44). There were no significant differences in therapeutic mastectomy, or breast conservation or lumpectomy rates between individuals with P/LP and VUS, or in any outcomes between patients with VUS and B/LB. Studies evaluating screening outcomes were limited, and results were conflicting. Comprehensive analysis do not indicate that a significant number of individuals with VUS results undergo inappropriate clinical management.

摘要

变异意义不确定(VUS)的不当医学使用仍然是遗传性癌症基因检测中的一个关注点。本研究的目的是评估致病性和可能致病性(P/LP)、VUS 以及良性和可能良性(B/LB)基因检测结果与癌症相关的手术和筛查管理之间的关联。从 1946 年到 2020 年 8 月 26 日,对 Medline、Embase、EBSCO CINAHL Plus 和 PsycINFO 进行了系统检索。符合条件的研究包括具有癌症基因检测结果和手术或筛查管理结果的个体。我们审查了 885 份摘要和 22 项研究,其中有 22 项研究报告了相关的手术和筛查结果。荟萃分析显示,与 VUS 相比,P/LP 个体的手术率显著更高,包括保乳手术与对侧预防性乳房切除术(OR=7.35,95%CI,4.14-13.64)、预防性乳房切除术(OR=3.05,95%CI,1.5-6.19)和卵巢切除术(OR=6.46,95%CI,3.64-11.44)。P/LP 个体与 VUS 个体之间的保乳手术或乳房保留或肿瘤切除术率没有显著差异,或 VUS 个体与 B/LB 个体之间的任何结果均无显著差异。评估筛查结果的研究有限,结果存在冲突。综合分析表明,VUS 结果的个体中并没有相当数量的人接受不当的临床管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/dc32b015113f/nihms-1761635-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/c56b708f8fde/nihms-1761635-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/fe3667d3a958/nihms-1761635-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/fd6b4ba2f164/nihms-1761635-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/dc32b015113f/nihms-1761635-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/c56b708f8fde/nihms-1761635-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/fe3667d3a958/nihms-1761635-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/fd6b4ba2f164/nihms-1761635-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1ff/8672382/dc32b015113f/nihms-1761635-f0004.jpg

相似文献

1
Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.遗传性癌症中意义不明的变异个体的临床管理:系统评价和荟萃分析。
Clin Genet. 2021 Aug;100(2):119-131. doi: 10.1111/cge.13966. Epub 2021 Apr 21.
2
Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.BRCA1 或 BRCA2 基因突变意义不明患者的临床决策
Ann Surg Oncol. 2017 Oct;24(10):3067-3072. doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.
3
Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.采用 ACMG/AMP 2015 指南重新解读遗传性乳腺癌/卵巢癌患者中意义未明的 BRCA1 和 BRCA2 变异。
Breast Cancer. 2019 Jul;26(4):510-519. doi: 10.1007/s12282-019-00951-w. Epub 2019 Feb 6.
4
A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.BRCA1 和 BRCA2 变异的回顾性再阐释研究。
Clin Lab. 2024 Apr 1;70(4). doi: 10.7754/Clin.Lab.2023.230911.
5
Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.BRCA 检测中意义不明的变异:手术决策评估、风险感知和癌症困扰。
Clin Genet. 2013 Nov;84(5):464-72. doi: 10.1111/cge.12097. Epub 2013 Feb 20.
6
Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions.BRCA1 和 BRCA2 意义未明变异携带者的随访:变异再分类和手术决策。
Genet Med. 2011 Dec;13(12):998-1005. doi: 10.1097/GIM.0b013e318226fc15.
7
Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.在多基因 panel 检测时代具有不确定意义的变异的遗传性乳腺癌风险患者的临床管理。
Ann Surg Oncol. 2019 Oct;26(10):3389-3396. doi: 10.1245/s10434-019-07595-2. Epub 2019 Jul 24.
8
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.女性 BRCA1/2、PALB2、CHEK2 和 ATM 携带者的癌症风险管理。
Breast Cancer Res Treat. 2020 Jul;182(2):421-428. doi: 10.1007/s10549-020-05699-y. Epub 2020 May 22.
9
Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer.遗传性乳腺癌基因检测与多民族早期乳腺癌女性行对侧预防性乳房切除术的相关性研究。
JCO Oncol Pract. 2022 Apr;18(4):e472-e483. doi: 10.1200/OP.21.00322. Epub 2021 Oct 27.
10
The influence of BRCA variants of unknown significance on cancer risk management decision-making.BRCA 意义未明变异对癌症风险管理决策的影响。
J Gynecol Oncol. 2019 Jul;30(4):e60. doi: 10.3802/jgo.2019.30.e60. Epub 2019 Feb 27.

引用本文的文献

1
Evaluating Liquid Biopsy for Circulating Tumor DNA (ctDNA) Detection as a Complementary Diagnostic Tool in Thyroid Cancer Among Ecuadorian Women.评估液体活检检测循环肿瘤DNA(ctDNA)作为厄瓜多尔女性甲状腺癌辅助诊断工具的价值。
Int J Mol Sci. 2025 Jul 21;26(14):6987. doi: 10.3390/ijms26146987.
2
An Integrated Clinical, Germline, Somatic, and In Silico Approach to Assess a Novel PMS2 Gene Variant Identified in Two Unrelated Lynch Syndrome Families.一种综合临床、种系、体细胞和计算机模拟方法,用于评估在两个无关的林奇综合征家族中鉴定出的一种新型PMS2基因变异。
Cancers (Basel). 2025 Jul 11;17(14):2308. doi: 10.3390/cancers17142308.
3

本文引用的文献

1
Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk.遗传性癌症风险多重基因检测诊断率及患者体验的多中心前瞻性队列研究
JCO Precis Oncol. 2019 Mar 28;3. doi: 10.1200/PO.18.00217. eCollection 2019 Mar.
2
Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: a systematic review and meta-analysis.接受多基因检测或基因组测序的意义未明变异体的临床和心理结果:一项系统评价和荟萃分析
Genet Med. 2021 Jan;23(1):22-33. doi: 10.1038/s41436-020-00957-2. Epub 2020 Sep 14.
3
Investigation of a germline variant of uncertain significance (MRE11:c.1138C > T) identified by exome sequencing in a cancer-affected individual and co-segregation analysis in affected and unaffected family members.
对一名癌症患者外显子组测序鉴定出的意义未明的种系变异(MRE11:c.1138C > T)以及患病和未患病家庭成员的共分离分析进行研究。
Mol Biol Rep. 2025 May 31;52(1):530. doi: 10.1007/s11033-025-10645-6.
4
Reclassification of VUS in and using the new / ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system.使用新的/ENIGMA轨迹集对[具体内容]和[具体内容]中的VUS进行重新分类,证明了ClinGen ENIGMA专家小组规范相对于标准ACMG/AMP分类系统的优越性。
Genet Med Open. 2025 Jan 7;3:101961. doi: 10.1016/j.gimo.2024.101961. eCollection 2025.
5
Phenotypic evaluation of deep learning models for classifying germline variant pathogenicity.用于分类种系变异致病性的深度学习模型的表型评估。
NPJ Precis Oncol. 2024 Oct 19;8(1):235. doi: 10.1038/s41698-024-00710-x.
6
Psychological distress following multi-gene panel testing for hereditary breast and ovarian cancer risk.遗传性乳腺癌和卵巢癌风险多基因检测后的心理困扰
J Genet Couns. 2025 Apr;34(2):e1940. doi: 10.1002/jgc4.1940. Epub 2024 Jul 23.
7
Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022.2015 年至 2022 年间,非西班牙裔白人与非裔美国人/黑人中癌症易感基因种系变异的差异率。
JCO Precis Oncol. 2024 Jul;8:e2300715. doi: 10.1200/PO.23.00715.
8
Real-world evaluation of deep learning algorithms to classify functional pathogenic germline variants.用于对功能性致病种系变体进行分类的深度学习算法的真实世界评估。
medRxiv. 2024 Apr 7:2024.04.05.24305402. doi: 10.1101/2024.04.05.24305402.
9
Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.基于人群的多基因检测在乳腺癌和卵巢癌预防中的成本效益。
JAMA Netw Open. 2024 Feb 5;7(2):e2356078. doi: 10.1001/jamanetworkopen.2023.56078.
10
Genomic disparity impacts variant classification of cancer susceptibility genes in Turkish breast cancer patients.基因组差异影响土耳其乳腺癌患者中癌症易感性基因变异的分类。
Cancer Med. 2024 Feb;13(3):e6852. doi: 10.1002/cam4.6852. Epub 2024 Feb 2.
Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
多基因 panel 检测后的乳腺癌患者行对侧预防性乳房切除术的风险
Ann Surg Oncol. 2020 Nov;27(12):4613-4621. doi: 10.1245/s10434-020-08889-6. Epub 2020 Jul 27.
4
The impact of communicating uncertain test results in cancer genetic counseling: A systematic mixed studies review.癌症遗传咨询中沟通不确定检验结果的影响:系统混合研究综述。
Patient Educ Couns. 2020 Sep;103(9):1692-1708. doi: 10.1016/j.pec.2020.03.015. Epub 2020 Mar 19.
5
Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.遗传检测对黑乳腺癌幸存者风险管理行为的影响:一项纵向观察性研究。
Ann Surg Oncol. 2020 May;27(5):1659-1670. doi: 10.1245/s10434-019-07982-9. Epub 2019 Nov 1.
6
Patients' Medical and Psychosocial Experiences After Detection of a Variant With Multigene Panel Testing.多基因检测发现变异后患者的医学和心理社会经历。
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00300. Epub 2019 Mar 28.
7
Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.BRCA 相关癌症的风险评估、遗传咨询和基因检测:美国预防服务工作组推荐声明。
JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.
8
Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.在多基因 panel 检测时代具有不确定意义的变异的遗传性乳腺癌风险患者的临床管理。
Ann Surg Oncol. 2019 Oct;26(10):3389-3396. doi: 10.1245/s10434-019-07595-2. Epub 2019 Jul 24.
9
The influence of BRCA variants of unknown significance on cancer risk management decision-making.BRCA 意义未明变异对癌症风险管理决策的影响。
J Gynecol Oncol. 2019 Jul;30(4):e60. doi: 10.3802/jgo.2019.30.e60. Epub 2019 Feb 27.
10
Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.乳腺癌诊断后种系多基因测序的检测结果和预后。
JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.